These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14676628)

  • 1. Clinical, genetic, and therapeutic insights into systemic mast cell disease.
    Tefferi A; Pardanani A
    Curr Opin Hematol; 2004 Jan; 11(1):58-64. PubMed ID: 14676628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of systemic mast cell disease: beyond interferon.
    Tefferi A
    Leuk Res; 2004 Mar; 28(3):223-4. PubMed ID: 14687615
    [No Abstract]   [Full Text] [Related]  

  • 5. [Systemic mastocytosis].
    Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
    Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 7. Eosinophilia in mast cell disease.
    Kovalszki A; Weller PF
    Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
    Bain BJ
    Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
    Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
    Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.
    Tefferi A; Lasho TL; Brockman SR; Elliott MA; Dispenzieri A; Pardanani A
    Haematologica; 2004 Jul; 89(7):871-3. PubMed ID: 15257945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
    J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin lesions and mast cells.
    Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
    Pardanani A
    Acta Haematol; 2005; 114(1):41-51. PubMed ID: 15995324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On being metachromatic: mystique and misunderstanding in mastocytosis.
    Gotlib J
    Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
    Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
    J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.